The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Hiraoka, Sakiko ^a   Kato, Jun ^b   Moritou, Yuki ^a   Takei, Daisuke ^a   Inokuchi, Toshihiro ^a   Nakarai, Asuka ^a   Takahashi, Sakuma ^a   Harada, Keita ^a   Okada, Hiroyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Remission; Single nucleotide polymorphisms; Tacrolimus; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOCHROME P450 3A5; HEMOGLOBIN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ABCB1 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CYP3A5 GENE; DEFECATION; DIET; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FATIGUE; FEMALE; GENETIC ANALYSIS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY DISEASE; LEUKOCYTE COUNT; MALE; MINIMUM PLASMA CONCENTRATION; NAUSEA; PREDICTION; REMISSION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHILD; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929619873     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0285-3     Document Type: Article

References (18)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.
2. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-10.
3. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-5.
4. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7-12.
5. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28:589-97.
6. Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother. 2012;46:1315-21.
7. Inoue T, Murano M, Narabayashi K, Okada T, Nouda S, Ishida K, et al. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern Med. 2013;52:15-20.
8. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159-68.
9. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-80.
10. Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-54.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-91.
12. Hirai F, Takatsu N, Yano Y, Satou Y, Takahashi H, Ishikawa S, et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. J Gastroenterol Hepatol. 2014;29:60-6.
13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J. 1955;2:1041-8.
14. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-62.
15. Ogata H, Kato J, Hirai F, Iida M, Takazoe M, Suzuki Y, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803-8.
16. Elens L, Bouamar R, Hesselink DA, Haufroid V, Van der Heiden IP, Van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-83.
17. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
18. Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204-13.